EnzeneX™ - Fully-connected continuous manufacturing™

EnzeneX™ is Enzene’s commercially validated Fully-Connected Continuous Manufacturing™ (FCCM™) platform, transforming how biologics and monoclonal antibodies are developed and produced. With the launch of EnzeneX™ 2.0 in both India and the United States, this next-generation platform is set to revolutionize global biologics manufacturing through a unique combination of high productivity, cost-efficiency, modular scalability, and environmental sustainability.

Unlike traditional fed-batch and semi-continuous systems, EnzeneX™ integrates a fully connected, end-to-end continuous process—from cell culture to purification—operating 24/7 with minimal hold times. This enables up to 10x higher yields and up to 50% lower cost of goods (COGS), with production costs targeted as low as $40 per gram. Such efficiencies make EnzeneX™ a game-changing solution for emerging biotech companies seeking affordable, high-quality biologics.

The platform’s modular design requires only 1,500 sq. ft., allowing for rapid deployment, reduced capital investment, and scalable operations. Single-use technologies reduce cleaning needs and contribute to a 50% reduction in greenhouse gas emissions, water usage, and energy consumption, supporting global sustainability goals.

EnzeneX™ also ensures exceptional product quality, particularly for difficult-to-express or unstable proteins such as fusion proteins, cytokines, and bi-/multi-specific antibodies. By minimizing product exposure to cell culture fluids, it reduces degradation risks like oxidation, clipping, deamination, and glycation.

Now being deployed in both India and the U.S., EnzeneX™ brings state-of-the-art continuous manufacturing to diverse markets. As the only commercially validated platform of its kind, EnzeneX™ is a catalyst for global health transformation, delivering affordable, sustainable, and scalable biologics manufacturing for a better future.